Sep 27, 2020|

JD Begins Selling Two Breakthrough Cancer Drugs


by Hui Zhang

JD Health collaborated with global pharmaceutical giant AstraZeneca to bring two breakthrough cancer drugs, Gefitinib (trade name: Iressa) and Osimertinib (trade name: Tagrisso), to JD Pharmacy, the company’s first-party pharmaceutical business store, making it easier for cancer patients to access the drugs online.

Both drugs are widely regarded as among the most effective ones for cancer treatment.
Osimertinib, which is a medication used to treat non-small-cell lung carcinomas with specific mutations, was found to reduce the risk of disease progression following surgery by up to 80%. Gefitinib is a novel targeted therapy that inhibits the tyrosine kinase activity of the epidermal growth factor receptor by competitively blocking the ATP binding site, with highly successful results.

Based on a closed loop of “doctors + drugs”, JD Health’s professional online medical consultation services and convenient drug purchase services have gained trust from more and more consumers across China. By joining hands with AstraZeneca, JD Health will promote the accessibility of Gefitinib, Osimertinib and other cancer drugs through fully integrating online-offline sources to make it convenient for patients to access medication.

“JD Health and AstraZeneca will actively collaborate to explore chronic lung cancer management through these two drugs, Gefitinib and Osimertinib,” said Enlin Jin, general manager of JD Pharmacy. “Additionally, both sides will work with industry associations, medical institutions and other partners in the field to jointly promote the construction of an integrated lung cancer treatment center in the future.”

As the most common malignant tumor in the world, lung cancer ranks first in cancer incidence and mortality, with the number of lung cancer cases in China reaching 784,000 in 2015, and the number of deaths due to lung cancer rising to 631,000, based on the report released by The National Cancer Center of China in 2019. In China, non-small cell lung cancer accounts for 80%~85% of all lung cancers, which is the most common type of lung cancer. The emergence and application of targeted drugs have enabled an increasing number of lung cancer patients to live beyond five years.